 CAMBRIDGE, Mass., Oct. 11, 2021 GLOBE NEWSWIRE -- Relay Therapeutics, Inc. Nasdaq: RLAY, a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of 350 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent 15 of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Relay Therapeutics. 